RNXT

RenovoRx, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.55
52-Week Range: $0.70 – $2.59
Market Cap: $71.30M
P/E (TTM): —
EPS (TTM): -0.31
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 7.94
PEG Ratio: —
Return on Equity: -125.23%
Return on Assets: -64.90%
Gross Margin: 84.41%
Operating Margin: -368.43%
Profit Margin: 0.00%
Current Ratio: 5.74
Debt/Equity: 0.04
Total Debt: $390.00K
Free Cash Flow: $-6.65M
Revenue Growth: 115.40%
Earnings Growth: —
Enterprise Value: $62.22M

RNXT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$43.00K	$1.12M
Cost of Revenue	—	$0.00	$0.00	$327.00K
Gross Profit	—	$0.00	$43.00K	$796.00K
Research & Development	$4.30M	$5.67M	$6.03M	$6.27M
Selling, General & Admin	$5.65M	$5.73M	$4.99M	$7.04M
Operating Expenses	$9.95M	$11.40M	$11.01M	$13.31M
Operating Income	-$9.95M	-$11.40M	-$10.97M	-$12.51M
EBITDA	-$9.94M	-$11.40M	-$10.97M	-$12.51M
Pretax Income	-$9.89M	-$10.23M	-$8.81M	-$11.17M
Net Income	-$9.89M	-$10.23M	-$8.81M	-$11.17M
Diluted EPS	-1.09	-0.99	-0.40	-0.32
Diluted Shares	9.05M	10.29M	22.27M	35.33M

RNXT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.39M	$1.17M	$7.15M	$7.02M
Receivables	—	$0.00	$43.00K	$139.00K
Inventory	—	—	$0.00	$189.00K
Current Assets	$7.26M	$1.47M	$7.83M	$7.89M
Total Assets	$7.26M	$1.47M	$8.12M	$8.10M
Current Liabilities	$1.10M	$1.18M	$1.91M	$1.96M
Total Debt	—	$0.00	$278.00K	$212.00K
Total Liabilities	$1.10M	$4.47M	$3.64M	$2.67M
Retained Earnings	-$31.17M	-$41.41M	-$50.22M	-$61.39M
Shareholders' Equity	$6.16M	-$3.00M	$4.48M	$5.42M
Working Capital	$6.16M	$291.00K	$5.92M	$5.93M

RNXT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$8.81M	-$10.26M	-$9.13M	-$10.97M
Capital Expenditure	—	—	-$12.00K	-$2.00K
Free Cash Flow	-$8.81M	-$10.26M	-$9.14M	-$10.97M
Depreciation & Amortisation	$6.00K	$0.00	$0.00	$2.00K
Stock-Based Compensation	$644.00K	$1.08M	$1.17M	$1.27M
Investing Cash Flow	-$2.03M	$2.03M	-$12.00K	-$2.00K
Financing Cash Flow	$42.00K	$5.01M	$15.12M	$10.85M
Net Change in Cash	-$10.80M	-$3.22M	$5.98M	-$130.00K

RNXT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$197.00K	$422.00K	$266.00K	$238.00K	$563.00K	$909.00K
Cost of Revenue	$94.00K	$152.00K	$53.00K	$28.00K	$84.00K	$143.00K
Gross Profit	$103.00K	$270.00K	$213.00K	$210.00K	$479.00K	$766.00K
Research & Development	$1.64M	$1.43M	$1.69M	$1.50M	$1.23M	$1.20M
Selling, General & Admin	$1.57M	$1.52M	$1.73M	$2.23M	$2.72M	$2.92M
Operating Expenses	$3.21M	$2.95M	$3.41M	$3.73M	$3.95M	$4.12M
Operating Income	-$3.11M	-$2.68M	-$3.20M	-$3.52M	-$3.47M	-$3.35M
EBITDA	-$3.11M	-$2.68M	-$3.20M	-$3.52M	-$3.47M	-$3.34M
Pretax Income	-$2.42M	-$2.90M	-$2.91M	-$2.94M	-$3.52M	-$2.91M
Net Income	-$2.42M	-$2.90M	-$2.91M	-$2.94M	-$3.52M	-$2.91M
Diluted EPS	-0.08	-0.08	-0.08	—	-0.09	-0.06
Diluted Shares	31.40M	36.58M	36.65M	—	38.03M	47.30M

RNXT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$14.58M	$12.31M	$10.04M	$7.02M	$12.36M	$9.48M
Receivables	$242.00K	$363.00K	$169.00K	$139.00K	$280.00K	$480.00K
Inventory	—	—	$272.00K	$189.00K	$379.00K	$383.00K
Current Assets	$15.74M	$13.39M	$10.98M	$7.89M	$13.72M	$10.81M
Total Assets	$16.01M	$13.64M	$11.21M	$8.10M	$13.96M	$11.47M
Current Liabilities	$1.74M	$1.56M	$1.88M	$1.96M	$1.92M	$1.88M
Total Debt	$283.00K	$260.00K	$236.00K	$212.00K	$186.00K	$390.00K
Total Liabilities	$2.86M	$3.00M	$3.13M	$2.67M	$2.70M	$2.49M
Retained Earnings	-$52.64M	-$55.53M	-$58.45M	-$61.39M	-$64.91M	-$67.82M
Shareholders' Equity	$13.16M	$10.64M	$8.08M	$5.42M	$11.27M	$8.98M
Working Capital	$14.01M	$11.84M	$9.10M	$5.93M	$11.80M	$8.93M

RNXT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.38M	-$2.30M	-$2.27M	-$3.02M	-$3.71M	-$2.87M
Capital Expenditure	-$2.00K	—	—	—	—	—
Free Cash Flow	-$3.38M	-$2.30M	-$2.27M	-$3.02M	-$3.71M	-$2.94M
Depreciation & Amortisation	$1.00K	$1.00K	-$1.00K	$1.00K	$1.00K	$5.00K
Stock-Based Compensation	$288.00K	$345.00K	$349.00K	$285.00K	$317.00K	$570.00K
Investing Cash Flow	-$2.00K	$0.00	$0.00	$0.00	$0.00	-$71.00K
Financing Cash Flow	$10.81M	$34.00K	$0.00	$0.00	$9.05M	$55.00K
Net Change in Cash	$7.43M	-$2.27M	-$2.27M	-$3.02M	$5.34M	-$2.88M

Market Snapshot

About

RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical need cancers. The company focuses on intra-arterial delivery technology that enables localized, intensive treatment of tumors while minimizing systemic exposure. RenovoRx is advancing its pipeline with a focus on pancreatic cancer and other solid tumors.